Drug Trial Radar · NCT00211198
Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)
Last checked: Nov 20, 2026Latest source record: Mar 5, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
May 2001
Primary completion
Jan 2005
Study completion Jan 2006
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- Collaborators
- Tufts Medical Center; National Cancer Institute (NCI); Ligand Pharmaceuticals
- First posted
- Sep 21, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research study is to evaluate how effective ONTAK is in the treatment of cutaneous T-cell Lymphoma (CTCL) and determine whether the presence of a type of protein called CD25 on the cancer cells makes a difference in how the body responds to the treatment. The hypothesis is that there is no difference in response rate for patients whose tumor cells are CD25 positive or negative.
Conditions
- Lymphoma, T-Cell, Cutaneous
Interventions
ONTAK (denileukin difitox, DAB389IL-2)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- To estimate response rates (CR + CCR + PR) according to CD25 status (CD25 positive and negative) after 4 cycles of ONTAK.
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California
Yale University School of Medicine
New Haven, Connecticut
The University of Iowa
Iowa City, Iowa
New England Medical Center
Boston, Massachusetts
University Hospitals of Cleveland
Cleveland, Ohio
Ohio State University
Columbus, Ohio
University of Pittsburgh
Pittsburgh, Pennsylvania
Vanderbilt University
Nashville, Tennessee
The University of Texas MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.